search scholar.google.com.

Papers Published

1. Heggestad, JT; Kinnamon, DS; Olson, LB; Liu, J; Kelly, G; Wall, SA; Oshabaheebwa, S; Quinn, Z; Fontes, CM; Joh, DY; Hucknall, AM; Pieper, C; Anderson, JG; Naqvi, IA; Chen, L; Que, LG; Oguin, T; Nair, SK; Sullenger, BA; Woods, CW; Burke, TW; Sempowski, GD; Kraft, BD; Chilkoti, A, Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test., Sci Adv, vol. 7 no. 26 (June, 2021), pp. eabg4901 [doi] .
   (last updated on 2024/04/17)

   Abstract:
   Highly sensitive, specific, and point-of-care (POC) serological assays are an essential tool to manage coronavirus disease 2019 (COVID-19). Here, we report on a microfluidic POC test that can profile the antibody response against multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens-spike S1 (S1), nucleocapsid (N), and the receptor binding domain (RBD)-simultaneously from 60 μl of blood, plasma, or serum. We assessed the levels of antibodies in plasma samples from 31 individuals (with longitudinal sampling) with severe COVID-19, 41 healthy individuals, and 18 individuals with seasonal coronavirus infections. This POC assay achieved high sensitivity and specificity, tracked seroconversion, and showed good concordance with a live virus microneutralization assay. We can also detect a prognostic biomarker of severity, IP-10 (interferon-γ-induced protein 10), on the same chip. Because our test requires minimal user intervention and is read by a handheld detector, it can be globally deployed to combat COVID-19.